Addressing the Clinical Infrastructure for Alzheimer’s Disease Potential Changes to Reduce Capacity Limitations and Facilitate Access to Care

Marwan N. Sabbagh, MD, FAAN

This activity is jointly provided by Global Education Group and Integritas Communications.


This activity is supported by an educational grant from Biogen MA, Inc.


Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objective

After completing this activity, the participant should be better able to:

  • Detail clinical infrastructure changes that may be needed to address the growing population of patients with AD and new treatment options

Statement of Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Though there are currently only symptomatic therapies available, amyloid- and tau-targeted therapies are on the horizon. With the approval of new therapies for AD, particularly monoclonal antibodies administered via infusion, clinic infrastructure will need to quickly adapt to select patients most appropriate for newly available therapy, demonstrate patient eligibility, provide on-site resources and equipment for patients and clinicians, and work with managed care to ensure coverage for these therapies.2-4 Changes on this scale will be challenging for everyone, ranging from small, private practices to large clinics at academic centers, and it is in clinicians’ and patients’ best interest to begin preparation for the coming changes now. Dr. Sabbagh provides his expert insight into how clinicians can prepare for significant changes in clinic infrastructure, the types of protocols that will be necessary, and strategies to work with managed care to facilitate patient access to newly approved therapies.


  1. Alzheimer’s Association. 2020 Alzheimer’s Disease Facts and Figures.
    Accessed November 5, 2020.
  2. Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1)1:1-4.
  3. Fleming WK, et al. JAMA Health Forum. 2020;1(9):e201148-e201148.
  4. Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hour(s) of pharmacology).

Term of Offering

This activity was released on April 21, 2021 and is valid for 1 year. Requests for credit must be made no later than April 21, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN Consultant/Independent Contractor: Acadia Pharmaceuticals, Inc., Alzheon Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations; Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC; Stock Shareholder: Athira Pharma, Brain Health Inc, NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS

System Requirements

Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome, or Firefox

MAC OS 10.2.8
Internet Explorer is not supported on the Macintosh.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 04/22/2022